Related Articles
Endobronchial pigmented mass in a patient with primary malignant melanoma of the lung: A case report
Comparative safety of BRAF and MEK inhibitors (vemurafenib, dabrafenib and trametinib) in first‑line therapy for BRAF‑mutated metastatic melanoma
Potential immune‑related adverse events during dabrafenib and trametinib treatment: A case series of patients with BRAF V600E melanoma
Malignant gastrointestinal neuroectodermal tumor with BRAF mutation and a history of malignant melanoma: A case report
Targeting the PI3K/AKT/mTOR pathway overcomes the stimulating effect of dabrafenib on the invasive behavior of melanoma cells with acquired resistance to the BRAF inhibitor